---
symbol: "LLY"
name: "Eli Lilly"
date: 2026-11-11
change_pct: 1.508819154211231
direction: "up"
event_type: "clinical_trial"
url: "https://perplo.app/why/LLY/2026-11-11"
updated_at: 2026-11-11T00:07:04.164Z
---

# Why Eli Lilly (LLY) rose 1.51% on November 11, 2026

Eli Lilly (LLY) rose 1.51% on November 11, 2026 — Foundayo trial cuts apnea, aids weight outlook.

## What happened

Lilly's Foundayo trial hit its primary target, significantly cutting the apnea-hypopnea index, and at 52 weeks it also improved weight and cardiovascular risk factors.

## Why it moved

Efficacy that holds across several endpoints at once, not just one, widens the addressable market for obesity and sleep apnea, so investors are pricing in a larger commercial opportunity for the drug.

## Why it matters

Within Healthcare & Biotech, Lilly is the bellwether for the GLP-1 franchise, and each new indication extends that demand story beyond diabetes and weight loss.

## What would break the thesis

A safety signal emerging from the data, or a final readout that weakens the headline efficacy numbers, would undercut the move.

## Sources

- [ELI LILLY: FOUNDAYO SIGNIFICANTLY REDUCES APNEA-HYPOPNEA INDEX, IMPROVES WEIGHT AND CARDIOVASCULAR RISK FACTORS AT 52-WEEKS](https://t.me/marketfeed/1073794) — MarketFeed
- [HIMS CFO SAYS IT EXPECTS THE ELI LILLY PARTNERSHIP TO IMPROVE PLATFORM RETENTION, AND THAT IT INTENTIONALLY PACED Q3 MARKETING SPEND ON WEIGHT-LOSS DRUGS AHEAD OF EXPANSIONS](https://t.me/marketfeed/1074187) — MarketFeed
- [$LLY](https://t.me/marketfeed/1073791) — MarketFeed

---

Trade LLY perpetual futures 24/7 onchain: https://perplo.app/asset/LLY